-
Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE
•
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607) announced a series of partnerships with prominent pharmaceutical companies, spanning domestic and international entities. Expanding Collaborations in Pharmaceutical InnovationFrance’s Sanofi (NASDAQ: SNY) has agreed to deepen its existing partnership with SPH, initially…
-
Ocumension Therapeutics’ OT-502 Receives NMPA Acceptance for Post-Cataract Inflammation Treatment
•
Ocumension Therapeutics (HKG: 1477) announced on September 23, 2024, that the National Medical Products Administration (NMPA) in China has accepted its New Drug Application (NDA) for OT-502 (DEXYCU, dexamethasone implant). This ophthalmic new drug is designed to treat postoperative inflammation and is indicated for suppressing inflammation and related complications in…
-
Ocumension Therapeutics’ Zerviate Receives Marketing Approval in China for Allergic Conjunctivitis Treatment
•
Ocumension Therapeutics (HKG: 1477), a leading ophthalmology specialist in China, has announced that its histamine H1 receptor-targeted drug Zerviate (OT-1001) has been granted marketing approval in China with priority review status. The drug is indicated for the treatment of itching symptoms associated with allergic conjunctivitis. Zerviate, originally developed by the…
-
Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights
•
Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1477), has declared its intent to proceed with a share repurchase program, targeting 10% of the total issued shares, excluding treasury shares. This initiative, which is not to exceed HKD 200 million, is…
-
Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China
•
Ocumension Therapeutics (HKG: 1477), a biopharmaceutical company based in China, has entered into a strategic partnership with Alcon Laboratories Inc., a global leader in eye care and a subsidiary of Novartis. Under the terms of the agreement, Alcon will provide Ocumension with research and development, manufacturing, and commercialization rights for…
-
Ocumension Therapeutics and Shandong Boan Biotechnology File for Market Approval of Biosimilar Aflibercept in China
•
Ocumension Therapeutics (HKG: 1477) and Shandong Boan Biotechnology Co., Ltd (HKG: 6955) have jointly announced the submission of a market approval filing to the National Medical Products Administration (NMPA) for their co-developed biosimilar version of Bayer’s Eylea (aflibercept). This biosimilar has the potential to be the latest entry in the…
-
Ocumension Therapeutics Sells $56.66 Million Stake in EyePoint Pharmaceuticals
•
Ocumension Therapeutics (HKG: 1477), a specialist in the ophthalmology sector in China, has announced plans to sell 2,910,501 shares of EyePoint Pharmaceuticals Inc., (NASDAQ: EYPT), representing a 5.96% stake in the US company. The transaction is expected to generate proceeds of USD 56.66 million (HKD 443 million). EyePoint Pharmaceuticals, established…
